Elon Musk Won’t Take COVID-19 Vaccine

Elon Musk’s Covid-19 Tests: Tesla CEO Says He Tests Both Positive and Negative

Elon Musk Won't Take COVID-19 VaccineElon Musk received mixed results after being tested for COVID-19 and is currently experiencing symptoms of a common cold. Musk says he was tested four times using a rapid antigen test: two tests came back positive and two came back negative.

He’s also awaiting the results from two PCR tests but the results won’t be known for 24 hours.

Antigen tests work by detecting a small protein on the surface of the coronavirus, whereas the more accurate PCR tests look for the virus itself.

Antigen tests can be conducted quickly as they don’t require a lab, and are often administered in hotspots like college campuses or elderly care facilities. “Positive results from antigen tests are highly accurate, but there is a higher chance of false negatives,” the FDA tells us, (That’s why PCR tests are ordered for confirmation.) One such antigen test from Quidel can detect the coronavirus 85 percent of the time. Musk says his antigen test came from BD.

Nevertheless, Musk, long a COVID-19 skeptic, questions the validity of the testing with just a hint of conspirac Elon Musk (@elonmusk)

Elon Musk Won’t Take COVID-19 Vaccine

Elon Musk says he won’t take coronavirus vaccine, calls Bill Gates a ‘knucklehead’ | New York Post

Covid 19 Flu Shot Risk

Robert. F. Kennedy, Jr. speaks with RT America about Remdesivir, a drug to treat COVID; Anthony Fauci, the chronic health conditions of children, and the risk of taking a flu shot.

Remdesivir Gets FDA Approval, but WHO Says Drug Ineffective for COVID

As far back as April, U.S. National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci was touting Gilead’s antiviral remdesivir as “the standard of care for patients with COVID-19.”

Remdesivir is the only antiviral authorized in the U.S. to treat COVID and is also authorized for use in roughly 50 countries. Yet the drug has absolutely no effect on a COVID patient’s chances of survival, according to recent data from the World Health Organization (WHO).

Starting in March 2020, WHO’s Solidarity Trial followed 11,266 adults in 30 countries to study the effects on COVID of four antivirals: remdesivir, hydroxychloroquine, lopinavir, and interferon. On Oct. 15, WHO reported that remdesivir not only failed to produce any measurable benefit in terms of mortality reduction, but that it also didn’t reduce the need for ventilators, or the length of hospital stays.

After WHO issued its report, remdesivir’s manufacturer, Gilead, was quick to point out that the Solidarity Trial hasn’t been peer reviewed or published in a scholarly journal. In a statement, the company said: “It is unclear if any conclusive findings can be drawn from the study results.”

Brooklyn’s Orthodox Jewish burn masks in protests as New York cracks down on rising coronavirus cases

Covid19 Virus Depopulation Vaccines Masks

Jacob Kornbluh was just three blocks from his home in Brooklyn, documenting a protest against coronavirus restrictions on Wednesday evening, when the demonstration suddenly turned toward him.

The 39-year-old journalist found himself pinned to the wall of a store, he said, as dozens of fellow Orthodox Jews began yelling and calling him a “moyser” — Yiddish for “snitch” — in a confrontation captured on video. Then a few maskless men spit onto his face.

“These were members of my own community with hatred in their eyes, flipping the finger toward me, calling me a Nazi, saying I deserve to die,” Kornbluh, a politics reporter for Jewish Insider, told The Washington Post. “All these months I keep a distance, wear a mask not to get sick, advocate for measures that save lives, they disrespect my space and do something horrifying.”

Leading COVID Vaccine Candidates Plagued by Safety Concerns

Unproven technologies, unsafe ingredients and inadequate testing — fortunately, current law prohibits mandating unlicensed vaccines approved for “emergency use.”

“It works!” trumpeted the normally stoic Nature journal about Pfizer’s early release results in a Phase III trial of its vaccine for COVID-19. Pfizer stated the vaccine was 90% effective when trial participants were exposed to SARS CoV-2, the virus said to cause COVID-19 symptoms.

Not so fast. Pfizer’s study protocol states cases count even if a trial participant has a positive test and only one symptom — like a cough, chills or diarrhea — that could easily be caused by one of 1,400 human pathogens, including 200 viruses known to infect humans. Except for Hepatitis A, B, C and HIV, the study protocol is silent on testing for other infectious causes of the participant’s symptoms.

In other words, the study suffers from confirmation bias. A cough and a positive test equals COVID, even when an “alternative possible diagnosis” could be the real cause of the symptoms. Absence of evidence is not evidence of absence.

Pfizer, partnering with BioNTech, uses new messenger RNA (mRNA) technology in their vaccine, and will apply for a coveted Emergency Use Authorization from the U.S. Food and Drug Administration (FDA), likely before the end of November. Pfizer’s announcement comes after 94 trial participants — of more than 43,000 — tested positive for SARS CoV-2. Pfizer has not released data on whether the cases were mild, moderate or severe.

Early results may sound encouraging to some, but experts like Eric Topol, director of the Scripps Research Translational Institute, indicated “the vaccine may not turn out to be as effective once the trial is complete and all the data has been analysed [sic],” however “its effectiveness is likely to stay well above 50%.” Pfizer’s study protocol (p. 103) states “success at the final analysis” will achieve a minimum 30% efficacy, with greater than 98% certainty. We hope the vaccine is not 30 to 90% effective against mild illness.

Will the Pfizer vaccine work, and is it safe? Questions remain. Any vaccine, including all COVID-19 vaccines, must be proven both safe and effective before being administered to high-risk groups or to the global population.

A successful vaccine must prevent severe illness, hospitalizations or death, without serious adverse events that outweigh these benefits. It cannot just claim to prevent mild cases that would resolve on their own. It must also prevent person-to-person transmission. The trial data must be sufficiently powered to answer these questions, not just for the healthy, but for high-risk groups such as the elderly and those with underlying conditions.

Illegal to mandate vaccines under Emergency Use Authorization

Any COVID vaccine(s) approved for emergency use should be voluntary, since the vaccine(s) are considered investigational and are held to a much lower standard for both efficacy and safety. For example, compared to the non-emergency approval process to get full licensure, an emergency approval allows for a vaccine that “may” be effective, compared to the non-emergency approval process where a vaccine must demonstrate “substantial” effectiveness.

Emergency Use Authorization (EUA) law is clear: States are barred from mandating a vaccine approved for emergency usage. (See Section VI. Preemption.) It also should be illegal for private businesses, airlines or your employer to mandate a vaccination while it is approved under an EUA.  By Alix Mayer


Comments are closed.